<SEC-DOCUMENT>0001157523-23-001048.txt : 20230629
<SEC-HEADER>0001157523-23-001048.hdr.sgml : 20230629
<ACCEPTANCE-DATETIME>20230629090122
ACCESSION NUMBER:		0001157523-23-001048
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230629
FILED AS OF DATE:		20230629
DATE AS OF CHANGE:		20230629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		231054594

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53437385.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="font-family: 'Times New Roman', serif;">&#160;
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; font-family: 'Times New Roman',serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <font style="font-size: 16pt;"> </font>
    <div style="text-align: center; font-family: 'Times New Roman',serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <font style="font-size: 16pt;"> </font>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-family: 'Times New Roman', serif; font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div style="font-family: 'Times New Roman', serif; font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">For the month of June 2023</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
    <div style="font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">(Translation of registrant&#8217;s name into English)</div>
    <div style="font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">(Address of principal executive office)</div>
    <div style="font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">Form 20-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Form 40-F&#160; <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">&#160;</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">&#160; <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z05494d32ce81415792a2255adf92c4fd">

        <tr>
          <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', serif; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', serif; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 9%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;"><a href="a53437385ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 1%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 90%; vertical-align: bottom;">
            <div style="text-align: justify; font-family: 'Times New Roman', serif;"><a href="a53437385ex99_1.htm">Press Release dated June 29, 2023.</a></div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; font-family: 'Times New Roman', serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; text-indent: 24pt; font-family: 'Times New Roman', serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div style="font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zef2e415ea0a14ab9a1815e8311125be9">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif; font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">Date: June 29, 2023</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', serif; font-style: italic;">/s/ Brad McConn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">Brad McConn</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; font-family: 'Times New Roman', serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze5316d97c62c4521a1560292c56aaf0c">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', serif;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman', serif;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53437385ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1<br>
    </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"><br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.</b> </h1>
      <div class="bw-release-subhead">
        <p><b> <i>The Company to host an earnings conference call via webcast</i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--June 29, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the &#8220;Company&#8221; or &#8220;IPA&#8221;) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today announced that it will host a
            conference call to discuss its quarterly results and recent business highlights for fourth quarter and fiscal year end 2023, on Friday, July 7, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the
            call. </p>
          <p> ImmunoPrecise management will host the conference call followed by a question-and-answer period. </p>
          <p> <b>Conference Call: <br>
            </b><b>Event Date: July 07, 2023 <br>
            </b><b>Event Time: 10:30 ET</b> </p>
          <p> <b>Participant Details:</b> </p>
          <p> <b>Conference ID: 9236374 <br>
            </b><b>Participant Toll-Free Dial-In Number: 1 (888) 550-5658 <br>
            </b><b>Participant Toll Dial-In Number: 1 (646) 960-0289 <br>
            </b><b>Attendee URL: </b><b>https://events.q4inc.com/attendee/109374701</b> </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About ImmunoPrecise Antibodies Ltd</b> </p>
          <p> ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V.
            (collectively, the &#8220;IPA Family&#8221;). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in
            bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics
            against the most challenging targets. For further information, visit www.ipatherapeutics.com. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Investor contact: investors@immunoprecise.com</b> </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
